414 related articles for article (PubMed ID: 33335028)
21. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
22. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M; Gallagher K; Chen YB; Leick MB; McAfee SL; El-Jawahri AR; DeFilipp Z; Horick N; O'Donnell P; Spitzer T; Dey B; Cook D; Trailor M; Lindell K; Maus MV; Frigault MJ
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 34996813
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
24. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.
Yi D; Gergis M; Elgohary G; Hsu J; Yang Y; Bi X; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):66-72. PubMed ID: 36537908
[TBL] [Abstract][Full Text] [Related]
25. CAR T Cells.
Nair R; Westin J
Adv Exp Med Biol; 2021; 1342():297-317. PubMed ID: 34972970
[TBL] [Abstract][Full Text] [Related]
26. Molecular and Clinical Characteristics of Different Toxicity Rates in Anti-CD19 Chimeric Antigen Receptor T Cells: Real-World Experience.
Gavriilaki E; Mallouri D; Bousiou Z; Demosthenous C; Vardi A; Dolgyras P; Batsis I; Stroggyli E; Karvouni P; Masmanidou M; Gavriilaki M; Bouinta A; Bitsianis S; Kapravelos N; Bitzani M; Vasileiadou G; Yannaki E; Sotiropoulos D; Papagiannopoulos S; Kazis D; Kimiskidis V; Anagnostopoulos A; Sakellari I
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686529
[TBL] [Abstract][Full Text] [Related]
27. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
28. Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations.
Halford Z; Anderson MK; Bennett LL; Moody J
Ann Pharmacother; 2021 Apr; 55(4):466-479. PubMed ID: 32762363
[TBL] [Abstract][Full Text] [Related]
29. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
[TBL] [Abstract][Full Text] [Related]
30. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
31. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens LA; Adams S; Cimino-Mathews A; Disis ML; Gatti-Mays ME; Ho AY; Kalinsky K; McArthur HL; Mittendorf EA; Nanda R; Page DB; Rugo HS; Rubin KM; Soliman H; Spears PA; Tolaney SM; Litton JK
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389617
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies.
Xiao X; Huang S; Chen S; Wang Y; Sun Q; Xu X; Li Y
J Exp Clin Cancer Res; 2021 Nov; 40(1):367. PubMed ID: 34794490
[TBL] [Abstract][Full Text] [Related]
33. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
34. Management Principles Associated With Cytokine Release Syndrome.
Baer B; Dudley CV; Simons RM
Semin Oncol Nurs; 2019 Oct; 35(5):150931. PubMed ID: 31477411
[TBL] [Abstract][Full Text] [Related]
35. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.
Pennisi M; Jain T; Santomasso BD; Mead E; Wudhikarn K; Silverberg ML; Batlevi Y; Shouval R; Devlin SM; Batlevi C; Brentjens RJ; Dahi PB; Diamonte C; Giralt S; Halton EF; Maloy M; Palomba ML; Sanchez-Escamilla M; Sauter CS; Scordo M; Shah G; Park JH; Perales MA
Blood Adv; 2020 Feb; 4(4):676-686. PubMed ID: 32084260
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.
Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J
Front Oncol; 2021; 11():698607. PubMed ID: 34381720
[TBL] [Abstract][Full Text] [Related]
37. Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.
Subklewe M; von Bergwelt-Baildon M; Humpe A
Transfus Med Hemother; 2019 Feb; 46(1):15-24. PubMed ID: 31244578
[TBL] [Abstract][Full Text] [Related]
38. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
39. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.
Anderson MK; Torosyan A; Halford Z
Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597
[TBL] [Abstract][Full Text] [Related]
40. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.
Silk AW; Barker CA; Bhatia S; Bollin KB; Chandra S; Eroglu Z; Gastman BR; Kendra KL; Kluger H; Lipson EJ; Madden K; Miller DM; Nghiem P; Pavlick AC; Puzanov I; Rabinowits G; Ruiz ES; Sondak VK; Tavss EA; Tetzlaff MT; Brownell I
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
